May 21, 2022
Loading...
You are here:  Home  >  'migraine'
Latest

Amgen, Novartis sue each other over migraine drug Aimovig

By   /  Friday, April 5th, 2019  /  East Ventura County, Health Care & Life Science, Latest news, Law & Goverment  /  Comments Off on Amgen, Novartis sue each other over migraine drug Aimovig

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen gets FDA approval for migraine drug Aimovig

By   /  Thursday, May 17th, 2018  /  East Ventura County, Health Care & Life Science, Latest news, Technology  /  Comments Off on Amgen gets FDA approval for migraine drug Aimovig

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen clinical trial shows promising results for migraine drug Aimovig

By   /  Tuesday, April 17th, 2018  /  East Ventura County, Health Care & Life Science, Latest news, Technology  /  Comments Off on Amgen clinical trial shows promising results for migraine drug Aimovig

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen announces positive results for migraine drug

By   /  Thursday, September 29th, 2016  /  Health Care & Life Science, Latest news  /  Comments Off on Amgen announces positive results for migraine drug

Thousand Oaks-based biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine days in patients with episodic migraines treated with Erenumab compared with a placebo. In the Read More →